261 related articles for article (PubMed ID: 14502007)
21. Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.
Gathe J; Badaro R; Grimwood A; Abrams L; Klesczewski K; Cross A; McLaren C
J Acquir Immune Defic Syndr; 2002 Dec; 31(4):399-403. PubMed ID: 12447010
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Duvivier C; Myrto A; Marcelin AG; Ghosn J; Ait-Mohand H; Schneider L; Agher R; Bricaire F; Costagliola D; Calvez V; Peytavin G; Katlama C
Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
[TBL] [Abstract][Full Text] [Related]
23. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
25. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.
Funk MB; Linde R; Wintergerst U; Notheis G; Hoffmann F; Schuster T; Kornhuber B; Ahrens P; Kreuz W
AIDS; 1999 Sep; 13(13):1653-8. PubMed ID: 10509566
[TBL] [Abstract][Full Text] [Related]
26. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
Aboulker JP; Babiker A; Chaix ML; Compagnucci A; Darbyshire J; Debré M; Faye A; Giaquinto C; Gibb DM; Harper L; Saïdi Y; Walker AS;
AIDS; 2004 Jan; 18(2):237-45. PubMed ID: 15075541
[TBL] [Abstract][Full Text] [Related]
27. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
29. Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.
Canestri A; Sow PS; Vray M; Ngom F; M'boup S; Kane CT; Delaporte E; Gueye M; Peytavin G; Girard PM; Landman R;
MedGenMed; 2007 Oct; 9(4):7. PubMed ID: 18311357
[TBL] [Abstract][Full Text] [Related]
30. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
[TBL] [Abstract][Full Text] [Related]
32. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
33. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
Ruxrungtham K; Kroon ED; Ungsedhapand C; Teeratakulpisarn S; Ubolyam S; Buranapraditkun S; van Leeuwen R; Weverling GJ; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
AIDS; 2000 Jul; 14(10):1375-82. PubMed ID: 10930152
[TBL] [Abstract][Full Text] [Related]
34. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Ribera E; Azuaje C; Lopez RM; Domingo P; Soriano A; Pou L; Sánchez P; Mallolas J; Sambea MA; Falco V; Ocaña I; Lopez-Colomes JL; Gatell JM; Pahissa A
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):317-23. PubMed ID: 16249706
[TBL] [Abstract][Full Text] [Related]
35. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
[TBL] [Abstract][Full Text] [Related]
36. Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.
Kazatchkine MD; Van PN; Costagliola D; Mohammed AS; Ledeine JM; Troccaz M; Belec L
J Acquir Immune Defic Syndr; 2000 Aug; 24(5):418-24. PubMed ID: 11035612
[TBL] [Abstract][Full Text] [Related]
37. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
39. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
40. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
